Shares of Avidity Biosciences RNA have soared 36% in the past month, all thanks to a report issued by the Financial Times (FT ...

" data-display-label="0" data-show-count="1" data-bookmark-label="Save" data-bookmarked-label="Saved" data-loggedin="0" data-type="post" data-object_id="338625" class="cbxwpbkmarktrig ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Citi wrote that concerns regarding Entresto going generic in the US may start fading away as the company continues to supply ...

Novartis has made a takeover approach for rare disease-focused biotech Avidity Biosciences, as Big Pharma continues to hunt for deals to offset looming patent cliffs, according to people familiar with ...

The Swiss pharmaceutical company is bracing for the patent expiration--and the arrival of generic competitors--for its heart drug Entresto, the group's best-selling medicine, at a time investors ...

Divi's Laboratories' custom synthesis segment has clocked strong year-on-year growth of 19% in the financial year 2025.

After an unusual first quarter in which seven of the biopharma industry’s | Several U.S. pharma companies that had posted ...

Divis Laboratories rose 1.94% to Rs 6143.35 after a foreign broker reiterated its 'buy' rating on the stock with a price target of Rs 7,750, citing attractive valuations and supportive sector ...